Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and
chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus
ipilimumab's safety and effectiveness in treating resectable NSCLC.
This study has multiple primary endpoints.
Phase
Phase 3
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Enrollment Eligibility
Inclusion Criteria:
- Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue
- Lung function capacity capable of tolerating the proposed lung surgery
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- Available tissue of primary lung tumor
Exclusion Criteria:
- Presence of locally advanced, inoperable or metastatic disease
- Participants with active, known or suspected autoimmune disease
- Prior treatment with any drug that targets T cell co-stimulations pathways (such as
checkpoint inhibitors)
Other protocol defined inclusion/exclusion criteria apply